Management of Hematologic Disorders

  • Author: David Aboulafia, MD (More Info)
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 4/1/16 (What's New)

Summary

  • HIV-infected patients generally have adequate erythropoietic capacity; however, small amounts of epoetin alfa can increase hemoglobin and significantly reduce transfusion requirements of those with anemia[Fischl 1990; Henry 1992]
  • Data from multiple studies evaluating increased hemoglobin target levels ≥ 13 g/dL using epoetin alfa have shown increased risk of cardiovascular events and death[Singh 2006; Drüeke 2006; Bohlius 2009]
  • CMS recommendations for erythropoiesis-stimulating agent use when hemoglobin levels decrease to < 10 g/dL and not > 12 g/dL are reasonable for patients with HIV (Table 5)

Action required